AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03424005
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
Trial: NCT03424005
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
Trial: NCT03424005
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
Trial: NCT03424005
Drug: Ribociclib (dose #1)
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib tablets will be administered by mouth once daily.
Trial: NCT02723578
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
Trial: NCT02723578
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg PO once daily on days 1-21 every 21 days
Trial: NCT03424005
Drug: Inavolisib (dose #2)
RxNorm normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inavolisib tablets will be administered by mouth once daily.
Trial: NCT03424005
Drug: Trastuzumab Deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
Trial: NCT03424005
Drug: Ribociclib (dose #2)
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib tablets will be administered by mouth once daily.
Trial: NCT03424005
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).
Trial: NCT00436527
Drug: Metronidazole gel 1%
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied once to a test site on the right or left cheek (as determined by a randomization design)
Trial: NCT00036582
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01497873
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
Trial: NCT01497873
Drug: Belotecan
RxNorm normalized name: belotecan
DrugBank: Belotecan (DB12459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
Trial: NCT03503227
Drug: Acetyl Salicylic acid
RxNorm normalized name: Acetyl salicylic acid specific IgE
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent
Trial: NCT00448682
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00448682
Drug: Floxuridine
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02573038
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
Trial: NCT05458726
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib or chemotherapy
Trial: NCT04173364
Drug: Ropivacaine 0.5% Injectable Solution
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injectable solution of ropivacaine 0.5%
Trial: NCT04173364
Drug: Ropivacaine 0.1% Injectable Solution
RxNorm normalized name: ROPivacaine 0.1% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dilution of ropivacaine to the concentration of 0.1%
Trial: NCT01741012
Drug: Gardasil
RxNorm normalized name: Gardasil
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
Trial: NCT02179775
Drug: propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01955980
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhalation
Trial: NCT01955980
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nasal Spray
Trial: NCT00448682
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03618082
Drug: Administration of the lowest effective concentration of desflurane (Interventional Group)
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).
Trial: NCT00634582
Drug: paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01408576
Drug: Epratuzumab
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
Trial: NCT01408576
Drug: Epratuzumab
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
Trial: NCT03424005
Drug: Inavolisib (dose #1)
RxNorm normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inavolisib tablets will be administered by mouth once daily.
Trial: NCT03424005
Drug: Inavolisib
RxNorm normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inavolisib tablets will be administered by mouth once daily.
Trial: NCT00433329
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
Trial: NCT00433329
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
Trial: NCT04195698
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib will be administered oral as tablet
Trial: NCT02017600
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 70 mg/m2 on day1
Trial: NCT02557594
Drug: Viread 300mg
RxNorm normalized name: Viread 300mg Tablet
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose administration after 10hr fasting
Trial: NCT02557594
Drug: DA-2802 319mg
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration after 10hr fasting
Trial: NCT01292460
Drug: Timolol/ FDC/ Placebo/ Tafluprost
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).
Trial: NCT00802529
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 transtympanic injections at interval of two weeks.
Trial: NCT02882074
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human albumin 5% during surgery
Trial: NCT02882074
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% Hydroxyethyl starch 130/0.4 during surgery
Trial: NCT01117051
Drug: prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 or 2 mg prucalopride once daily before breakfast
Trial: NCT00673270
Drug: Fludrocortisone
RxNorm normalized name: Fludrocortisone
DrugBank: Fludrocortisone (DB00687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg of fludrocortisone per os
Trial: NCT00673270
Drug: Placebo of Fludrocortisone
DrugBank: Fludrocortisone (DB00687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet of placebo of Fludrocortisone
Trial: NCT00206076
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
Trial: NCT00206076
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mycophenolate mofetil monotherapy
Trial: NCT02545231
Drug: Pitavastatin 1mg
RxNorm normalized name: PITAVASTATIN 1MG TAB
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
Trial: NCT02545231
Drug: Pitavastatin 4mg
RxNorm normalized name: PITAVASTATIN 4MG TAB
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
Trial: NCT02103361
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02103361
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03555578
Drug: Leuprorelin Acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin Acetate Injection Kit
Trial: NCT00461331
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
Trial: NCT00461331
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
Trial: NCT00882401
Drug: Ergocalciferol (Vitamin D)
RxNorm normalized name: ERGOCALCIFEROL (VITAMIN D) 25000 UNT CAP
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
Trial: NCT00057681
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrated until blood level is 1.1 to 1.3 mEq/L
Trial: NCT00057681
Drug: Valproate
RxNorm normalized name: Valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrated until blood level is 111 to 125 ug/mL
Trial: NCT00159666
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01757366
Drug: Ginsenoside Rg3 plus First-line Chemotherapy
RxNorm normalized name: ginsenoside
DrugBank: Ginsenoside Rg3 (DB19257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
Trial: NCT04921046
Drug: lignocaine
RxNorm normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After giving lignocaine to a group of people, myoclonus was observed after the dose of etomidate given two minutes after lignocaine.
Trial: NCT00057681
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
Trial: NCT01751802
Drug: Ecopipam
RxNorm normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antagonist of the dopamine D1 receptor
Trial: NCT01759888
Drug: 18F-DTBZ
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
Trial: NCT04921046
Drug: Midazolam 1 milligram Prefilled Syringe
RxNorm normalized name: midazolam Prefilled Syringe
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: after giving midazolam to the second group of people two minutes before etomidate dose, myoclonus was observed for one minute.
Trial: NCT03123848
Drug: Darunavir/Cobicistat
RxNorm normalized name: darunavir/cobicistat 800 mg-150 mg ORAL TABLET
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
Trial: NCT02659930
Drug: pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
Trial: NCT01369355
Drug: Ustekinumab 90 mg SC q8w
RxNorm normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
Trial: NCT01369355
Drug: Ustekinumab 130 mg IV
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
Trial: NCT01369355
Drug: Ustekinumab 90 mg SC q12w
RxNorm normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
Trial: NCT02319759
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
Trial: NCT02319759
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
Trial: NCT03131154
Drug: ADX-102 Ophthalmic Solution (0.5%)
RxNorm normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
Trial: NCT03131154
Drug: Vehicle of ADX-102 Ophthalmic Solution
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
Trial: NCT00024167
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
Trial: NCT00024167
Drug: Estramustine phosphate sodium
RxNorm normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
Trial: NCT00024167
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg orally (po) 3 x day, Days 1 through 7
Trial: NCT00024167
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg orally 2 x daily, weeks 1-14
Trial: NCT00024167
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
Trial: NCT00024167
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
Trial: NCT03610399
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different total dose and supervision.
Trial: NCT01936909
Drug: Anakinra (weeks 1-2)
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 100 mg daily for weeks 1 and 2
Trial: NCT01936909
Drug: Anakinra (weeks 3-12)
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02339064
Drug: apomorphine infusion
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
Trial: NCT00290979
Drug: insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT06424236
Drug: Gantenerumab
RxNorm normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label administered Subcutaneously every 4 weeks, at escalating doses; at target, dosing was every 2 weeks
Trial: NCT03565666
Drug: iLet Bionic Pancreas insulin-only configuration with Fiasp
RxNorm normalized name: insulin aspart, human Cartridge [Fiasp]
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)
Trial: NCT04016142
Drug: Carboplatin-Paclitaxel adjuvant chemotherapy
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)
Trial: NCT04577352
Drug: Vatiquinone
RxNorm normalized name: Vatiquinone
DrugBank: Vatiquinone (DB11917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vatiquinone will be administered per dose and schedule specified in the arm.
Trial: NCT00300118
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 9 mg
Trial: NCT00300118
Drug: mesalazine
RxNorm normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4.5 g
Trial: NCT02666703
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00033072
Drug: Selegiline
RxNorm normalized name: Selegiline
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no